MannKind

MannKind EBITDA per Employee

The EBITDA per Employee of MannKind (MNKD) as of Oct 11, 2026 is 72,253.38 USD. In the previous year, EBITDA per Employee was 122,613.18 USD — a change of -41.07% (lower).

EBITDA per Employee

72,253.38USD

YoY

-41.07%

Last updated:

EBITDA per Employee of MannKind is 2025 72,253.38 USD. EBITDA per Employee of MannKind was 2024 122,613.18 USD. It decreases by -41.07% lower compared to the previous year.

The MannKind EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-131,413.85 USD
Jan 1, 2019
-70,935.81 USD
Jan 1, 2020
-81,059.12 USD
Jan 1, 2021
-108,697.64 USD
Jan 1, 2022
-110,040.54 USD
Jan 1, 2023
14,658.78 USD
Jan 1, 2024
122,613.18 USD
Jan 1, 2025
72,253.38 USD
The MannKind EBITDA per Employee history
YEAREBITDA per EmployeeYoY
72,253.38USD-41.07%
122,613.18USD+736.45%
14,658.78USD-113.32%
-110,040.54USD+1.24%
-108,697.64USD+34.10%
-81,059.12USD+14.27%
-70,935.81USD-46.02%
-131,413.85USD-25.41%
-176,180.74USD-255.07%
113,614.86USD-119.52%
-582,187.50USD+91.87%
-303,423.99USD—
Access this data via the Eulerpool API

MannKind Stock analysis

What does MannKind do? MannKind Corp is a biopharmaceutical company that specializes in the development, production, and marketing of inhalable medications. The company was founded in 1991 by renowned scientist Alfred E. Mann and is headquartered in Westlake Village, California. MannKind Corp's history began with its founding in 1991 and the development of technologies for manufacturing injectable drugs. Over the years, the company has continuously evolved its technologies and now specializes in inhalable medications. MannKind Corp offers a wide portfolio of products in various areas, with the main areas being diabetes, lung and respiratory diseases, and cancer and immunology. The company develops and produces innovative medications and inhalation devices that allow patients to fight their illnesses. In particular, MannKind Corp has achieved significant success in the field of diabetes treatment. The company has developed an inhalable insulin solution that allows patients to quickly and easily inhale insulin. This novel insulin preparation called Afrezza was launched in the U.S. market in 2015 and greatly improves the treatment of both Type 1 and Type 2 diabetes. With Afrezza, MannKind Corp has achieved a milestone in medical history. In addition to Afrezza, MannKind is also working on other promising projects such as an inhalable drug for COPD (chronic obstructive pulmonary disease), an inhalable painkiller, and a cancer medication. The company also operates its own research department to develop new drugs and therapies. To realize its business model, the company utilizes partnerships and joint ventures to successfully bring its products to market. For example, it has formed a partnership with Sanofi, a globally leading biopharmaceutical company, to launch Afrezza in Europe. It has also established a partnership with Receptor Life Sciences Inc. in the U.S. to develop an inhalable cannabinoid medication for neuropathic pain. MannKind Corp is a company with ambitious goals and visions. It has already made significant advancements in development and elevated the treatment of diseases to a higher level. With its innovative products and technologies, the company remains a leading player in the biopharmaceutical industry and contributes to improving people's lives. MannKind is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MannKind stock

EBITDA per Employee of MannKind is 72,253.38 USD in 2025.

EBITDA per Employee of MannKind changed from 122,613.18 USD to 72,253.38 USD, representing a -41.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee MannKind since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's MannKind historically and in real time.

Access this data via the Eulerpool API

Workforce — MannKind

All Key Metrics — MannKind